Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.

Autor: Arguello-Tomas M; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Albiol N; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Hematology Department, Catalan Institute of Oncology (ICO), Hospital Universitari Doctor Josep Trueta, Girona, Spain., Jara P; Josep Carreras Leukemia Research Institute, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Garcia-Cadenas I; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Redondo S; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Esquirol A; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Novelli S; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Saavedra S; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Martino R; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Nomdedeu J; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Mora A; Sant Pau Institute for Biomedical Research, Barcelona, Spain., Moreno C; Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona.; Josep Carreras Leukemia Research Institute, Barcelona.; Medicine department, Universitat Autònoma de Barcelona, Barcelona.; Sant Pau Institute for Biomedical Research, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2023 Oct; Vol. 64 (10), pp. 1655-1661. Date of Electronic Publication: 2023 Jul 15.
DOI: 10.1080/10428194.2023.2232489
Abstrakt: Treatment of chronic lymphocytic leukemia (CLL) has dramatically evolved over the last decades thanks to the introduction of targeted therapies. We aimed to describe retrospectively the evolution in the frontline prescription in the CLL patients from our institution. As a secondary objective, the impact of frontline therapy on the time-to-next-treatment (TTNT) and overall survival (OS). After a median of 6.4 years (0.1-36.4) of follow-up from diagnosis, 323 of 780 CLL patients (41.4%) required therapy. Alkylating agents in monotherapy (chlorambucil) were the most used until 2012, and from then, chemoimmunotherapy. Since 2018, targeted therapies were the most common therapeutic strategy (74.1%). Patients who received targeted therapies had significantly longer TTNT compared to other regimens. In the multivariable analyses, mutated IGHV genes targeted therapies and chemoimmunotherapy regimens were related to longer TTNT, and sex female, age younger than 65, and mutated IGHV genes were associated with better OS.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje